Royalty Pharma Sub-Manager, LLC

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed August 21, 2026), Royalty Pharma Sub-Manager, LLC reported 4 stock positions worth $172.8 million. Its top holding was Cytokinetics (CYTK) at 37.4% of the portfolio, followed by Zenas Biopharma (ZBIO, 27.0%) and Biocryst Pharmaceuticals (BCRX, 21.2%). Compared with Q4 2025, it added to 1. The biggest buy was Zenas Biopharma (ZBIO, shares +89%).

Most Recent 13F
Q2 2026
Location
New York, NY
CIK
0002081668
Portfolio Value
$172.8M (Q1 2026)
SEC Filing
0002081668-26-000017 ↗ filed Aug 21, 2026

Holdings Value

0$50.0M$100.0M$150.0M$200.0M$250.0M Q4 2025: $171.3M Q4 2025 Q1 2026: $172.8M $172.8M Q1 2026 Q2 2026: $241.9M Q2 2026

Holdings 4 stocks · $172.8M
CYTK Cytokinetics Inc. 37.40% 980,392 $64.6M No change
ZBIO Zenas Biopharma Inc. 27.02% 2,388,150 $46.7M Add +89.1%
BCRX Biocryst Pharmaceuticals Inc. 21.19% 3,846,154 $36.6M No change
BHVN Biohaven Ltd. 14.38% 2,936,507 $24.8M No change

Portfolio Sells Q4 2025 → Q1 2026
None this quarter.

Portfolio Buys Q4 2025 → Q1 2026
ZBIO Zenas Biopharma Inc. Add +89.1% 27.02% +0.25

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026Amended 4$241.9MCYTK, ZBIO, KLRA, BHVN
Q1 2026Amended 4$172.8MCYTK, ZBIO, BCRX, BHVN
Q4 2025Amended 4$171.3MCYTK, ZBIO, BHVN, BCRX